BioChain Acquires China Rights to Epigenomics' Lung Cancer IVD

BioChain, a US-China diagnostics/genomics tools company, has in-licensed China rights to a novel blood-based lung cancer diagnostic test from Epigenomics of Germany. BioChain will conduct China clinical trials for approval of the test in China and then commercialize it. In 2013, BioChain and Epigonomics entered a similar agreement for Epigenomics' Septin9-based colorectal cancer blood-test, which BioChain launched in 2015. More details.... Share this with colleagues: // //